Back to Search
Start Over
Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
- Source :
- Blood; November 2022, Vol. 140 Issue: Supplement 1 p9647-9649, 3p
- Publication Year :
- 2022
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 140
- Issue :
- Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs61221898
- Full Text :
- https://doi.org/10.1182/blood-2022-164444